ClinicalTrials.gg
WithdrawnNCT04305678Updated Nov 20, 2024

Mepolizumab for Eosinophilic Fasciitis

A Phase 1 interventional study of Mepolizumab in Eosinophilic Fasciitis, sponsored by Mayo Clinic. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Mayo Clinic · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Funding lost from Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a proof of concept pilot study to investigate the efficacy of mepolizumab in the treatment of eosinophilic fasciitis.

Read the detailed description

This is an exploratory study designed to generate preliminary data in evaluating the efficacy of mepolizumab (Nucala) in the treatment of EF using mean change in the Rodnan Skin score (mRSS) before and after treatment. The study is powered at 90% to detect a 4 point change in the mRSS at a 5% significant level with a minimum target accrual of 6 patients.

02

Conditions studied

  • Eosinophilic Fasciitis

Keywords

  • Mepolizumab
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18 years or older.
  • History and physical examination consistent with EF
  • Full thickness skin characteristic of eosinophilic fascitis and/or MRI radiographic findings characteristic of EF
  • Documented peripheral eosinophilia (≥500 microliter)
  • Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and
  • Patients who read and sign an approved for this study

Exclusion criteria

Exclusion Criteria:

  • Eosinophilic fascitis disease duration > 5 years
  • Known history of adverse reaction to mepolizumab (Nucala)
  • Pregnant females
  • Females actively trying to conceive
  • Vulnerable study population
  • Asthma requiring inhaled cortiosteroids
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Single Arm

    Patients with a biopsy proven diagnosis of eosinophilic fasciitis

    Drug: Mepolizumab

Interventions

  • Mepolizumab (Nucala) 400 mg SC every 4 weeks x 24 weeks

    Also known as: Nucala

06

What researchers measure

Primary outcomes

  1. Modified Rodnan Skin Score (mRSS)

    Mean change before and after treatment. The mRSS is a standardized scored assessment of tissue sclerosis as assessed by palpitation.

    Time frame: 24 weeks

Secondary outcomes

  1. Localized Scleroderma Skin Severity Index (mLoSSI) score

    Mean change before and after treatment. mLoSSI score quantifies disease activity.

    Time frame: 24 weeks

  2. Localized Scleroderma Damage Index (LoSDI) score.

    Mean change before and after treatment. LoSDI score quantifies disease damage.

    Time frame: 24 weeks

  3. Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)

    Mean change before and after treatment. LoSCAT is a composite score of disease activity (mLoSSI) and disease damage (LoSDI).

    Time frame: 24 weeks

  4. Physician's Global Assessment of Disease Activity (PhysGA-A)

    Mean change before and after treatment. PhysGA-A is a 100-mm analog scale anchored by "inactive" at 0 and "markedly active" at 100.

    Time frame: 24 weeks

  5. Physician's Global Assessment of Disease Damage (PhysGA-D)

    Mean change before and after treatment. PhysGA-D is a 100-mm analog scale anchored by "no damage" at 0 and "markedly damaged" at 100.

    Time frame: 24 weeks.

  6. Dermatology Quality of Life Index (DLQI)

    Mean change before and after treatment. DLQI is a skin-specific health questionnaire with higher scores reflecting decreased quality of life

    Time frame: 24 weeks.

  7. Patient Global Assessment of Disease Severity (PtGA-S)

    Mean change before and after treatment.PhysGA-A is a 100-mm analog scale anchored by "not severe" at 0 and "very severe" at 100.

    Time frame: 24 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2020
First posted
Mar 12, 2020
StartEst.
Feb 2023
Primary completionActual
Feb 15, 2023
CompletionActual
Feb 15, 2023
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04305678
Lead sponsor
Mayo Clinic
Collaborators
GlaxoSmithKline
Responsible party
Jason Sluzevich MD (Assistant Professor of Dermatology, College of Medicine, Mayo Clinic) — Principal investigator
First posted
Mar 12, 2020
Start date
Feb 2023 (estimated)
Primary completion
Feb 15, 2023
Completion
Feb 15, 2023
Last update
Nov 20, 2024

Study contacts

Jason C Sluzevich, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mepolizumab

Start the discussion